Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Findings challenge breast cancer screening norms

Written by | 6 Dec 2025

Researchers report that an analysis of data from outpatient facilities in the New York State region revealed that 20-24% of breast cancers breast cancers diagnosed in an 11-year… read more.

Eli Lilly to share late-breaking and new Phase III results highlighting continued momentum in breast oncology at SABCS 2025

Written by | 3 Dec 2025

Eli Lilly and Company announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking… read more.

Common heartburn and blood pressure medicines linked to adverse breast cancer outcomes in large global study

Written by | 14 Nov 2025

A major international study involving 23,000 people has found concerning evidence about the impact of a range of common, everyday medications on the treatment outcomes for patients with… read more.

Outdoor air pollution linked to higher incidence of breast cancer

Written by | 3 Nov 2025

Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according… read more.

Missing first screening appointment linked to higher risk of breast cancer death

Written by | 4 Oct 2025

Women who don’t turn up for their first breast screening appointment face a 40% higher long term risk of dying from breast cancer, mainly due to delayed detection,… read more.

Verzenio (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy – Eli Lilly

Written by | 18 Sep 2025

Eli Lilly and Company announced positive topline results from the primary overall survival (OS) analysis of the Phase III monarchE trial. Treatment with two years of Verzenio plus… read more.

Why breast cancer therapy tamoxifen may lead to higher risk of uterine cancer

Written by | 1 Sep 2025

In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast cancers are treated in the future Studies show that people… read more.

Low dose olanzapine cuts chemo-induced nausea without causing sedation

Written by | 31 Jul 2025

Low-dose (5mg) olanzapine reduces chemo-induced nausea in breast cancer patients without causing sedation, researchers reported on July 1, 2025 in The Lancet Oncology. As background for this study,… read more.

Breast cancer mortality lower among women with screening-detected tumors

Written by | 5 Jun 2025

Breast cancer detected by routine screening of women aged 40 years or older is associated with lower odds of advanced cancer, mastectomy, and breast cancer–related death compared with… read more.

One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment in 4,000-patient study over 10 years

Written by | 25 May 2025

Presented at ESTRO 2025, which gathered a record attendance of 7,908 participants this week in Vienna, Austria, a 10-year study, involving over 4,000 UK patients, confirms that a one-week… read more.

Can exercise and rehab services be integrated into breast cancer care?

Written by | 12 May 2025

A recent randomized controlled trial reveals the potential of a program designed to connect patients who have breast cancer to needed exercise and rehabilitation services starting at diagnosis… read more.

Breast cancer death rates have stopped going down

Written by | 17 Mar 2025

A new paper in the Journal of Breast Imaging, published by Oxford University Press, indicates that breast cancer mortality rates have stopped declining in women older than age 74, and… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.